Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6451 to 6465 of 7680 results

  1. Off-pump coronary artery bypass (OPCAB) (IPG35)

    This guidance has been updated and replaced by NICE interventional procedure guidance 377.

  2. Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG343)

    This guidance has been updated and replaced by NICE interventional procedure guidance 494.

  3. Health app: ChatHealth communication platform in school nursing services (MIB130)

    The health app briefing on ChatHealth communication platform in school nursing services has been withdrawn.

  4. Daylight for treating generalised anxiety disorder in adults (MIB309)

    August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.

  5. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued [GID-TA10047]

  6. SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

    Discontinued [GID-MT516]

  7. Abicipar pegol for treating wet age-related macular degeneration ID1533

    In development [GID-TA10511] Expected publication date: TBC

  8. Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]

    Discontinued [GID-TA10394]

  9. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued [GID-TA11119]

  10. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued [GID-TA10197]

  11. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued [GID-TA10149]

  12. Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]

    Discontinued [GID-TA10546]

  13. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued [GID-TA10355]